Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1980 Feb;39(2):526–531.

Inhibitory effect of heparin on leucocyte chemotactic factors.

B M Czarnetzki, W Panneck, P J Frosch
PMCID: PMC1538043  PMID: 6771079

Abstract

Heparin inhibits attraction of leucocytes to chemotactic factors in human skin windows in a dose-dependent fashion. These findings can be reproduced by in vitro chemotaxis studies with zymosan-activated serum, bacterial factor or eosinophil chemotactic factor as chemoattractants. Evidence is presented that the mechanism of this inhibition is an interaction of heparin with the chemotactic factors themselves and not with the migrating leucocytes. Two other mucopolysaccharides, chondroitin sulphate A and hyaluronic acid, are also potent inhibitors of chemotactic factors. These findings suggest a physiological mechanism whereby inflammatory processes can be modulated at tissue sites and within the peripheral circulation.

Full text

PDF
526

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aswanikumar S., Schiffmann E., Corcoran B. A., Wahl S. M. Role of a peptidase in phagocyte chemotaxis. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2439–2442. doi: 10.1073/pnas.73.7.2439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Avila J. L. The influence of the type of sulphate bond and degree of sulphation of glycosaminoglycans on their interaction with lysosomal enzymes. Biochem J. 1978 May 1;171(2):489–491. doi: 10.1042/bj1710489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Czarnetzki B. M., König W., Lichtenstein L. M. Eosinophil chemotactic factor (ECF). I. Release from polymorphonuclear leukocytes by the calcium ionophore A23187. J Immunol. 1976 Jul;117(1):229–234. [PubMed] [Google Scholar]
  4. Czarnetzki B., Sonak R., Macher E. Comparison of eosinophil chemotactic factor (ECF) in basophils and mast cells. Monogr Allergy. 1979;14:281–284. [PubMed] [Google Scholar]
  5. Fernandez H. N., Henson P. M., Otani A., Hugli T. E. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978 Jan;120(1):109–115. [PubMed] [Google Scholar]
  6. Goetzl E. J., Austen K. F. Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis. J Exp Med. 1976 Dec 1;144(6):1424–1437. doi: 10.1084/jem.144.6.1424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. König W., Czarnetzki B. M., Lichtenstein L. M. Eosinophil chemotactic factor (ECF). II. Release from human polymorphonuclear leukocytes during phagocytosis. J Immunol. 1976 Jul;117(1):235–241. [PubMed] [Google Scholar]
  8. Levy D. A., Osler A. G. Studies on the mechanisms of hypersensitivity phenomena. XV. Enhancement of passive sensitization of human leukocytes by heparin. J Immunol. 1967 Dec;99(6):1062–1067. [PubMed] [Google Scholar]
  9. Schiffmann E., Showell H. V., Corcoran B. A., Ward P. A., Smith E., Becker E. L. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol. 1975 Jun;114(6):1831–1837. [PubMed] [Google Scholar]
  10. Showell H. J., Freer R. J., Zigmond S. H., Schiffmann E., Aswanikumar S., Corcoran B., Becker E. L. The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils. J Exp Med. 1976 May 1;143(5):1154–1169. doi: 10.1084/jem.143.5.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Siraganian R. P., Hook W. A. Complement-induced histamine release from human basophils. II. Mechanism of the histamine release reaction. J Immunol. 1976 Mar;116(3):639–646. [PubMed] [Google Scholar]
  12. Slorach S. A. Histamine and heparin release from isolated rat mast cells exposed to compound 48-80. Acta Physiol Scand. 1971 May;82(1):91–97. doi: 10.1111/j.1748-1716.1971.tb04945.x. [DOI] [PubMed] [Google Scholar]
  13. Walb D., Loos M., Hadding U. In vitro-Untersuchungen über Angriffspunkt und Wirkungsunterschiede zum Heparin. Antikomplementäre Wirkung eines semisynthetischen Pentosan-Polysulfo-Esters. Z Naturforsch B. 1971 May;26(5):403–408. [PubMed] [Google Scholar]
  14. Ward P. A., Lepow I. H., Newman L. J. Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol. 1968 Apr;52(4):725–736. [PMC free article] [PubMed] [Google Scholar]
  15. Yoshida T., Amsden A., Ksiazek J., Cohen S. The effect of heparin on chemotactic and migration inhibitory lymphokines. Clin Immunol Immunopathol. 1978 Jul;10(3):287–291. doi: 10.1016/0090-1229(78)90183-6. [DOI] [PubMed] [Google Scholar]
  16. Yurt R. W., Leid R. W., Jr, Spragg J., Austen K. F. Immunologic release of heparin from purified rat peritoneal mast cells. J Immunol. 1977 Apr;118(4):1201–1207. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES